{"id":"W2735576184","doi":"10.1016/s2352-3018(17)30095-4","title":"Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study","year":2017,"lang":"en","type":"article","venue":"The Lancet HIV","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"ca_institutions":"University Health Network","funders":"ViiV Healthcare","keywords":"Dolutegravir; Emtricitabine; Medicine; Abacavir; Atazanavir; Ritonavir; Lamivudine; Raltegravir; Regimen; Population; Viral load; Internal medicine; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virus","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001059759,0.0005049214,0.001243392,0.0001781385,0.0006296882,0.0004121968,0.0003557242,0.0001296394,0.00002413084],"category_scores_gemma":[0.0003006466,0.0003285542,0.00002740492,0.0003221179,0.0002122897,0.0005718832,0.0004175326,0.0004336513,0.00005180275],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004389703,"about_ca_system_score_gemma":0.0002228871,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002880441,"about_ca_topic_score_gemma":0.0022276,"domain_scores_codex":[0.9973928,0.0002616441,0.000617069,0.0007559306,0.0003942653,0.000578342],"domain_scores_gemma":[0.9978673,0.0003310134,0.000469135,0.0009856595,0.000127182,0.0002196355],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6276098,0.01336643,0.2747976,0.0002327165,0.002774715,0.001423381,0.02563731,0.00001333432,0.002051086,0.00007449898,0.003682331,0.04833671],"study_design_scores_gemma":[0.602994,0.002905857,0.3899771,0.0004052105,0.000567694,0.00002455209,0.0004823719,0.00138826,0.0001343955,0.0000946593,0.0006072894,0.0004185741],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.988556,0.0002027635,0.00001359249,0.00331071,0.0001495528,0.005331166,0.0005269299,0.00008958732,0.001819752],"genre_scores_gemma":[0.9925884,0.0005505612,0.0002035475,0.00005293024,0.0001443388,0.0007384228,0.001504003,0.00005135135,0.004166464],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1151794,"threshold_uncertainty_score":0.9999167,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05353258789769456,"score_gpt":0.3366963371139196,"score_spread":0.283163749216225,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}